JP2023551539A - 放射性医薬品コンジュゲート組成物及びその使用 - Google Patents

放射性医薬品コンジュゲート組成物及びその使用 Download PDF

Info

Publication number
JP2023551539A
JP2023551539A JP2023533236A JP2023533236A JP2023551539A JP 2023551539 A JP2023551539 A JP 2023551539A JP 2023533236 A JP2023533236 A JP 2023533236A JP 2023533236 A JP2023533236 A JP 2023533236A JP 2023551539 A JP2023551539 A JP 2023551539A
Authority
JP
Japan
Prior art keywords
conjugate
peptide
amino acid
alkyl
bond
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023533236A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023551539A5 (cg-RX-API-DMAC10.html
Inventor
チャーリーチ，デボラ
リウ，ヂュインヂィエ
ソン，ケン
ノンコヴィッチ，アラン
コール，デレク
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Rayzebio Inc
Original Assignee
Rayzebio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Rayzebio Inc filed Critical Rayzebio Inc
Publication of JP2023551539A publication Critical patent/JP2023551539A/ja
Publication of JP2023551539A5 publication Critical patent/JP2023551539A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Physics & Mathematics (AREA)
  • Optics & Photonics (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
JP2023533236A 2020-11-30 2021-11-30 放射性医薬品コンジュゲート組成物及びその使用 Pending JP2023551539A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202063119555P 2020-11-30 2020-11-30
US63/119,555 2020-11-30
PCT/US2021/061186 WO2022115778A1 (en) 2020-11-30 2021-11-30 Radiopharmaceutical conjugate compositions and uses thereof

Publications (2)

Publication Number Publication Date
JP2023551539A true JP2023551539A (ja) 2023-12-08
JP2023551539A5 JP2023551539A5 (cg-RX-API-DMAC10.html) 2024-12-06

Family

ID=81753691

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023533236A Pending JP2023551539A (ja) 2020-11-30 2021-11-30 放射性医薬品コンジュゲート組成物及びその使用

Country Status (5)

Country Link
US (1) US20230158179A1 (cg-RX-API-DMAC10.html)
EP (1) EP4251639A1 (cg-RX-API-DMAC10.html)
JP (1) JP2023551539A (cg-RX-API-DMAC10.html)
CN (1) CN116888138A (cg-RX-API-DMAC10.html)
WO (1) WO2022115778A1 (cg-RX-API-DMAC10.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2023283882A1 (en) * 2022-06-10 2025-01-30 Peking University Trifunctional compound and use thereof
CN120091830A (zh) * 2022-08-24 2025-06-03 苏州创胜医药集团有限公司 使用抗cldn18.2抗体-放射性核素缀合物的非侵入性方法
CN117645652A (zh) * 2022-09-02 2024-03-05 核欣(苏州)医药科技有限公司 环肽及其制备方法、包括其的复合物、及其用途
US20260083865A1 (en) * 2022-09-07 2026-03-26 3B Pharmaceuticals Gmbh Prostate specific membrane antigen (psma) ligands and use thereof
JP2025532958A (ja) * 2022-09-29 2025-10-03 ペプチドリーム株式会社 ＥｐｈＡ２結合保留ペプチド及びそれを含む組成物
WO2024073622A2 (en) * 2022-09-29 2024-04-04 Rayzebio, Inc. Radiopharmaceutical compositions targeting ephrin type-a receptor 2 and uses thereof
WO2024183634A1 (en) * 2023-03-09 2024-09-12 Norroy Bioscience Co., Ltd. Radiolabeled antibody conjugates and uses thereof
JPWO2024195709A1 (cg-RX-API-DMAC10.html) * 2023-03-17 2024-09-26
CN118754936A (zh) * 2023-03-27 2024-10-11 晶核生物医药科技(南京)有限公司 环状多肽类化合物及其应用
EP4692105A1 (en) * 2023-03-27 2026-02-11 Bivision Pharmaceuticals, Inc Cyclic polypeptide compound and use thereof
KR20260009883A (ko) * 2023-05-24 2026-01-20 베이징 창핑 래보러토리 신규 삼관능 화합물 및 이의 용도
EP4719498A1 (en) * 2023-05-31 2026-04-08 Full-Life Technologies UK Limited Radioligands for targeting cell surface receptors and uses thereof
WO2024254339A2 (en) * 2023-06-07 2024-12-12 Rayzebio, Inc. Radiopharmaceutical compositions targeting glypican-3 and uses thereof
JP2026521249A (ja) * 2023-06-14 2026-06-29 マリアナ オンコロジー インコーポレーテッド Ｄｌｌ３標的化ペプチド及びその構築物
CR20260011A (es) * 2023-06-14 2026-05-15 Mariana Oncology Inc Péptidos dirigidos a dll3 y sus construcciones
AU2024304266A1 (en) * 2023-06-14 2025-12-04 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
UY40854A (es) * 2023-08-15 2025-02-28 Novartis Ag Péptidos cíclicos dirigidos a fap y conjugados de los mismos
TW202517674A (zh) 2023-10-19 2025-05-01 德商拜耳廠股份有限公司 抗gpc3抗體及其放射性結合物
WO2025117586A1 (en) * 2023-11-27 2025-06-05 Mariana Oncology Inc. Dll3 targeting peptides and constructs thereof
WO2025137443A1 (en) 2023-12-22 2025-06-26 Rayzebio, Inc. Radiopharmaceutical compositions targeting somatostatin receptors and uses thereof
WO2025179168A1 (en) * 2024-02-22 2025-08-28 Mariana Oncology Inc. Synthesis of dll3-binding peptides
CN119119174B (zh) * 2024-09-12 2025-08-08 重庆医科大学附属第二医院 一种靶向caix和fap的化合物、其核素标记物、制法和应用
WO2026128542A1 (en) * 2024-12-11 2026-06-18 Rayzebio, Inc. Radiopharmaceutical compositions targeting glypican-3 and uses thereof
CN119874832A (zh) * 2025-01-13 2025-04-25 重庆医科大学 一种新型多肽荧光探针的制备方法及应用

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08503924A (ja) * 1992-06-23 1996-04-30 ダイアテク，インコーポレイテッド 造影および治療用途の放射性標識ソマトスタチン誘導ペプチド
WO2015185162A1 (en) * 2014-06-06 2015-12-10 Technische Universität München Modified cyclopentapeptides and uses thereof
US20170240596A1 (en) * 2016-02-19 2017-08-24 The Curators Of The University Of Missouri Prostate-specific membrane antigen (psma) targeting peptides
WO2017223565A1 (en) * 2016-06-24 2017-12-28 University Of Iowa Research Foundation Compositions and methods of treating melanoma
WO2020097531A1 (en) * 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
JP2022541752A (ja) * 2019-07-08 2022-09-27 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP2022541753A (ja) * 2019-07-08 2022-09-27 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6017512A (en) 1992-06-23 2000-01-25 Diatide, Inc. Radiolabeled peptides

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH08503924A (ja) * 1992-06-23 1996-04-30 ダイアテク，インコーポレイテッド 造影および治療用途の放射性標識ソマトスタチン誘導ペプチド
WO2015185162A1 (en) * 2014-06-06 2015-12-10 Technische Universität München Modified cyclopentapeptides and uses thereof
US20170240596A1 (en) * 2016-02-19 2017-08-24 The Curators Of The University Of Missouri Prostate-specific membrane antigen (psma) targeting peptides
WO2017223565A1 (en) * 2016-06-24 2017-12-28 University Of Iowa Research Foundation Compositions and methods of treating melanoma
WO2020097531A1 (en) * 2018-11-08 2020-05-14 Indi Molecular, Inc. Theranostic capture agents, compositions, and methods of using and making
JP2022541752A (ja) * 2019-07-08 2022-09-27 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用
JP2022541753A (ja) * 2019-07-08 2022-09-27 ３ベー ファーマシューティカルズ ゲーエムベーハー 線維芽細胞活性化タンパク質リガンドを含む化合物およびその使用

Also Published As

Publication number Publication date
CN116888138A (zh) 2023-10-13
US20230158179A1 (en) 2023-05-25
WO2022115778A1 (en) 2022-06-02
EP4251639A1 (en) 2023-10-04

Similar Documents

Publication Publication Date Title
US20230158179A1 (en) Radiopharmaceutical conjugate compositions and uses thereof
JP7546574B2 (ja) 二重リガンド薬物コンジュゲート及びその使用
CA2978340C (en) Maytansinoid derivatives, conjugates thereof, and methods of use
KR102057356B1 (ko) Ｘｔｅｎ 콘주게이트 조성물 및 그의 제조 방법
CA3019835A1 (en) Methods and compositions for car t cell therapy
EP3474901A1 (en) Cleavable tetrazine used in bio-orthogonal drug activation
AU2012257417A1 (en) Bio-orthogonal drug activation
JP2021507928A (ja) 分岐連結体を備えたチューブリシン類縁体の共役体
CN115135628A (zh) 快速高效点击释放的化合物
WO2022115799A1 (en) Radiopharmaceutical conjugates targeting guanylyl cyclase c, and compositions and uses thereof
US20200230133A1 (en) Discrete PEG Constructs
JP2021501201A (ja) ステープルペプチドの細胞内送達のためのポリペプチド接合体
JP2021530545A (ja) 同種異系の細胞療法における抗−ｃｄ２抗体薬物コンジュゲート（ａｄｃ）の使用
JP2021532116A (ja) 同種異系の細胞療法における抗−ｃｄ５抗体薬物コンジュゲート（ａｄｃ）の使用
TW202504632A (zh) 靶向磷脂醯肌醇蛋白聚糖－３之肽組成物及其用途
WO2024073622A2 (en) Radiopharmaceutical compositions targeting ephrin type-a receptor 2 and uses thereof
CN112739339B (zh) 抗cd137抗体药物缀合物(adc)在同种异体细胞疗法中的用途
KR20260022328A (ko) 글리피칸-3을 표적화하는 방사성제약 조성물 및 그의 용도
EP4271702B1 (en) Chlorotoxin derivatives and use thereof
US20250222146A1 (en) Radiopharmaceuticals Targeting Somatostatin Receptor 2 and Uses Thereof
WO2025137443A1 (en) Radiopharmaceutical compositions targeting somatostatin receptors and uses thereof
TW202426031A (zh) ＥｐｈＡ２結合待定肽及包含其之組成物
KR20240087695A (ko) Car t-세포의 재생을 위한 접합체, 조성물 및 방법
HK40130456A (en) Bi-ligand drug conjugate and use thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230803

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20241128

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20241128

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20251110

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20260430